Fulcrum Therapeutics

OverviewSuggest Edit

The sequencing of the human genome has provided incredible insight into disease biology, yet the richness of biology comes from the dynamic on and off switches that control the genome – gene regulation. The Fulcrum product engine is based on the breakthrough biology of gene regulation. It will bring to bear medicines for devastating diseases across multiple therapeutic areas by modulating – or balancing – the expression of the genes known to drive disease. By focusing on disease causative genes, we are taking a highly personalized approach to treating disease – unlocking the druggable mechanisms that regulate disease genes to develop a new generation of disease-modifying therapies.
TypePublic
Founded2016
HQCambridge, MA, US
Websitefulcrumtx.com

Latest Updates

Employees (est.) (Jan 2021)432(+24%)
Job Openings9
Revenue (FY, 2020)$8.8 M
Share Price (Jun 2022)$5.1(+4%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Fulcrum Therapeutics

Bryan Stuart

Bryan Stuart

President, Chief Executive Officer, Board Member
Judith Dunn

Judith Dunn

President, Research & Development
Nicole T. Gallagher

Nicole T. Gallagher

Director, Administration
Kim Hazen

Kim Hazen

Senior Vice President, Human Resources
Curtis Oltmans

Curtis Oltmans

General Counsel
Peter Thomson

Peter Thomson

Vice President, Finance and Accounting
Show more

Fulcrum Therapeutics Office Locations

Fulcrum Therapeutics has an office in Cambridge
Cambridge, MA, US (HQ)
26 Landsdowne St
Show all (1)

Fulcrum Therapeutics Financials and Metrics

Fulcrum Therapeutics Revenue

Fulcrum Therapeutics's revenue was reported to be $8.82 m in FY, 2020
USD

Revenue (FY, 2020)

8.8m

Net income (FY, 2020)

(70.8m)

EBIT (FY, 2020)

(71.6m)

Market capitalization (23-Jun-2022)

207.2m

Closing stock price (23-Jun-2022)

5.1

Cash (31-Dec-2020)

57.1m
Fulcrum Therapeutics's current market capitalization is $207.2 m.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

8.8m

General and administrative expense

4.5m8.3m13.1m21.4m

R&D expense

18.5m25.2m71.1m59.0m

Operating expense total

23.0m33.5m84.2m80.4m
Quarterly
USDQ2, 2019Q1, 2020Q2, 2020

Revenue

750.0k2.0m

General and administrative expense

2.6m5.1m5.1m

R&D expense

10.9m14.5m12.8m

Operating expense total

13.5m19.5m17.9m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

407.0k72.8m96.7m57.1m

Accounts Receivable

2.0m

Prepaid Expenses

931.0k1.3m3.4m4.1m

Current Assets

1.3m74.1m100.1m119.5m
Quarterly
USDQ2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

49.6m101.6m25.4m75.7m

Prepaid Expenses

1.7m3.6m2.8m2.3m

Current Assets

51.4m105.2m84.3m134.8m

PP&E

10.0m9.6m9.4m8.9m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(23.0m)(32.6m)(82.7m)(70.8m)

Depreciation and Amortization

715.0k1.3m2.1m2.4m

Accounts Payable

208.0k(20.0k)803.0k1.8m

Cash From Operating Activities

(20.1m)(22.6m)(39.5m)(53.7m)
Quarterly
USDQ2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(50.0m)(66.6m)(18.5m)(34.1m)

Depreciation and Amortization

1.0m1.5m539.0k1.1m

Accounts Payable

451.0k2.8m1.4m1.4m

Cash From Operating Activities

(22.0m)(35.0m)(15.2m)(29.3m)
USDFY, 2017

Financial Leverage

3.3 x
Show all financial metrics

Fulcrum Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

SecurityScorecard logo

Fulcrum Therapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Fulcrum Therapeutics Online and Social Media Presence

Embed Graph

Fulcrum Therapeutics News and Updates

Fulcrum Therapeutics Announces Proof-of-Concept for FTX-6058 in Sickle Cell Disease Based on Initial Data from the Ongoing Phase 1b Trial

- Achieved up to 6.3% hemoglobin F (HbF) induction in initial subjects in first cohort; HbF was increasing at last measured timepoint

Fulcrum Therapeutics to Participate at the Upcoming BofA Securities 2022 Healthcare Conference

CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside chat at the Bo…

Fulcrum Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

CAMBRIDGE, Mass., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced closing of its previously announced underwritten public offer…

Fulcrum Therapeutics Announces Pricing of $125 Million Public Offering of Common Stock

CAMBRIDGE, Mass., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that it has priced an underwritten public offering of 6,600,0…

Thinking about buying stock in Newtek Business Services, Fulcrum Therapeutics, Gamida Cell, PubMatic, or Falcon Capital Acquisition?

NEW YORK, Aug. 11, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NEWT, FULC, GMDA, PUBM, and SHCR. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
Show more

Fulcrum Therapeutics Blogs

Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2022 Financial Results

– In itial data from Phase 1b trial of FTX-6058 in sickle cell disease to be presented at the EHA 2022 Congress – – Phase 3 REACH trial of losmapimod in FSHD expected to begin in 2Q 2022 – – Conference call scheduled for 8:00 a.m. ET today – CAMBRIDGE, Mass., May 09, 2022 (GLOBE NEWSWIRE) --

Fulcrum Therapeutics to Host First Quarter 2022 Financial Results Conference Call and Webcast on Monday, May 9, 2022 at 8:00 a.m. ET

CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ®  (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its first quarter 2022 financial results will be

Fulcrum Therapeutics® to Participate in 11th Annual SVB Leerink Global Healthcare Conference

CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.  (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside chat at the

Fulcrum Therapeutics® to Present at the 40th Annual J.P. Morgan Healthcare Conference

Fulcrum Therapeutics® to Present at the 40th Annual J.P. Morgan Healthcare Conference Content Import Thu, 01/06/2022 - 08:02 Fulcrum Therapeutics® to Present at the 40th Annual J.P. Morgan Healthcare Conference January 6, 2022 at 8:02 AM EST This release is a …

Fulcrum Therapeutics™ to Participate in Upcoming November Investor Conferences

Fulcrum Therapeutics™ to Participate in Upcoming November Investor Conferences Content Import Wed, 11/03/2021 - 07:00 Fulcrum Therapeutics™ to Participate in Upcoming November Investor Conferences November 3, 2021 at 7:00 AM EDT This release is a backfill from…

Fulcrum Therapeutics™ to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.  (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will be participating in the following
Show more

Fulcrum Therapeutics Frequently Asked Questions

  • When was Fulcrum Therapeutics founded?

    Fulcrum Therapeutics was founded in 2016.

  • Who are Fulcrum Therapeutics key executives?

    Fulcrum Therapeutics's key executives are Bryan Stuart, Judith Dunn and Nicole T. Gallagher.

  • How many employees does Fulcrum Therapeutics have?

    Fulcrum Therapeutics has 432 employees.

  • What is Fulcrum Therapeutics revenue?

    Latest Fulcrum Therapeutics annual revenue is $8.8 m.

  • What is Fulcrum Therapeutics revenue per employee?

    Latest Fulcrum Therapeutics revenue per employee is $20.4 k.

  • Who are Fulcrum Therapeutics competitors?

    Competitors of Fulcrum Therapeutics include Xenotherapeutics Inc, CytoTools and PamBio.

  • Where is Fulcrum Therapeutics headquarters?

    Fulcrum Therapeutics headquarters is located at 26 Landsdowne St, Cambridge.

  • Where are Fulcrum Therapeutics offices?

    Fulcrum Therapeutics has an office in Cambridge.

  • How many offices does Fulcrum Therapeutics have?

    Fulcrum Therapeutics has 1 office.